Pediatric/Adolescent Trials

The NeuroCognitive & Behavioral Institute (formerly The NeuroCognitive Institute) is currently enrolling volunteers for the following clinical trials.

• Attenuation of Anxiety Symptoms by Neuromodulating Amygdala: A Proof-of-Concept and Intent-to-Treat Study

Past Studies
Pediatric/Neurodevelopmental Disorders

• D1AMOND Study, a Phase 2B Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome
• A Randomized, Placebo-controlled Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette’s Disorder
• The T-Force Platinum Research Study
• A 12-Month Open-Label, Repeat-Dose Safety Study In Epilepsy Subjects
• A Phase 2b, Randomized, Double-Blind, Placebo-controlled, Dose Optimization Study to Assess the Safety, Tolerability and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects with Tourette Syndrome.
• A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and
• Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder. PI – 2012-2014
• Double Blind Phase IV trial on Patients with ADHD. PI – 2012 – 2013
• Open Label Phase IV trial on Patients with ADHD. PI – 2012-2013